Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used for providing adequate organ support in cardiogenic shock. While the intervention provides circulatory and respiratory support in the critical stage, it carries a high risk of life-threatening complications, including bleeding, infections, limb ischemia, and central nervous system infarction.^1,2 Novel approaches to improve weaning rates from VA-ECMO are crucial to mitigate morbidity and mortality associated with this high-risk intervention. Levosimendan has been linked to successful weaning from VA-ECMO in prior observational studies.^3,4 However, evidence from experimental studies remains limited. Therefore, we read with great interest the new study by Guinot et al. investigating the role of levosimendan in reducing weaning failure.⁵ This multicenter, double-blind, randomized controlled trial (RCT) evaluated the efficacy and safety of levosimendan versus placebo in 80 patients with refractory cardiogenic shock supported with VA-ECMO who met predetermined criteria for ECMO weaning.⁵ Given the potential benefits of levosimendan reported in prior literature, this RCT could provide valuable insights to validate existing evidence.

 

VA-ECMO is a highly effective modality for maintaining circulatory support. However, it is associated with severe complications such as hemorrhage, ischemic, and infectious events,¹ which heavily contribute to morbidity and mortality. Consequently, the weaning process from ECMO demands comprehensive clinical assessment and strategies to ensure patient safety. To date, weaning protocols remain multifactorial and there is no single, standardized method.^6,7 Various parameters and treatments associated with successful weaning have been reported.⁷ For instance, the etiology of cardiac failure, overall hemodynamic stability, ability to tolerate a full weaning trial, and echocardiographic assessment of cardiac parameters must be considered.⁷ In addition to physiological metrics, pharmacological management plays a pivotal role during the weaning process. This pharmacological support often includes vasopressors and inotropes, such as epinephrine, milrinone, and dobutamine, as well as now levosimendan.